Auxano Advisors LLC Purchases Shares of 1,587 Zoetis Inc. $ZTS

Auxano Advisors LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,587 shares of the company’s stock, valued at approximately $247,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Nuveen LLC purchased a new stake in Zoetis during the first quarter valued at $616,375,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Zoetis by 113.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after buying an additional 1,995,491 shares during the last quarter. Mackenzie Financial Corp raised its position in shares of Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after buying an additional 1,782,110 shares in the last quarter. Polen Capital Management LLC lifted its holdings in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares during the last quarter. Finally, Impax Asset Management Group plc lifted its holdings in shares of Zoetis by 362.6% in the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock valued at $182,705,000 after acquiring an additional 922,589 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

Shares of Zoetis stock opened at $116.96 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock’s fifty day moving average is $138.98 and its two-hundred day moving average is $150.66. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $181.85. The company has a market capitalization of $51.54 billion, a PE ratio of 20.13, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue was up .5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Analyst Ratings Changes

Several brokerages have weighed in on ZTS. Morgan Stanley reduced their price objective on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research note on Monday, November 10th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. JPMorgan Chase & Co. lowered their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. BTIG Research cut their price objective on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Finally, UBS Group reduced their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.